| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/26/2002 | DE10113402A1 New N,N'-bis-(Aminocarbonyl)-hydrazine derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, apoplexy, restenosis or tumors |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | DE10112041A1 p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate p-thienylbenzyl amides as agonists of angiotensin- (1-7) receptors, processes for their preparation, their use and pharmaceutical compositions containing them |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441510A1 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 09/26/2002 | CA2441503A1 Method for cleaving human growth hormone gh |
| 09/26/2002 | CA2441427A1 Biurethane derivatives |
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441289A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| 09/26/2002 | CA2441202A1 Chemical compounds |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440954A1 Phenyl derivatives 3 |
| 09/26/2002 | CA2440749A1 Isolation and purification procedure of vasopeptidase peptide inhibitors |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | CA2425902A1 Urocortin-iii and uses thereof |
| 09/26/2002 | CA2407681A1 Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine |
| 09/26/2002 | CA2403903A1 Angiogenesis inhibitors |
| 09/25/2002 | WO2001074354A1 DIURETICS CONTAINING η-TOCOTRIENOL |
| 09/25/2002 | EP1243595A1 Bh4-fused polypeptides |
| 09/25/2002 | EP1243589A1 Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses |
| 09/25/2002 | EP1243583A1 Heterocyclic compounds having sulfonamide groups |
| 09/25/2002 | EP1243582A1 Quinoline and quinazoline derivatives and drugs containing the same |
| 09/25/2002 | EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1242608A2 Method of achieving persistent transgene expression |
| 09/25/2002 | EP1242596A1 Methods and materials relating to novel von willebrand/thrombospondin-like polypeptides and polynucleotides |
| 09/25/2002 | EP1242592A2 A molecular switch for regulating mammalian gene expression |
| 09/25/2002 | EP1242584A2 Human kinases |
| 09/25/2002 | EP1242458A2 Brain specific binding members |
| 09/25/2002 | EP1242455A1 N-alkylated peptides having antiangiogenic activity |
| 09/25/2002 | EP1242452A2 Chimeric natriuretic peptides |
| 09/25/2002 | EP1242451A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242398A2 Partially saturated calcium channel blockers |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242381A2 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242118A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242103A1 Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof |
| 09/25/2002 | EP1242097A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 09/25/2002 | EP1242089A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 09/25/2002 | EP1242082A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 09/25/2002 | EP1242074A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 09/25/2002 | EP1242069A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 09/25/2002 | EP1242068A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 09/25/2002 | EP1242064A1 Liver selective therapy |
| 09/25/2002 | EP1242063A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 09/25/2002 | EP1242051A1 Novel forms of pravastatin sodium |
| 09/25/2002 | EP1242050A2 Survivin promotion of angiogenesis |
| 09/25/2002 | EP1241935A2 Methods for producing transgenic animals |
| 09/25/2002 | EP1175432A4 Processes for the synthesis of oligomers using phosphoramidite compositions |
| 09/25/2002 | EP1144408B1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application |
| 09/25/2002 | EP0986390B1 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 09/25/2002 | EP0972020B1 Insulin-like growth factor agonist molecules |
| 09/25/2002 | EP0942745B1 Use of hyaluronidase |
| 09/25/2002 | EP0925299B1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 09/25/2002 | EP0923550B1 Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists |
| 09/25/2002 | EP0817782B1 Phenyl derivatives useful as endothelin receptor antagonists |
| 09/25/2002 | EP0806958A4 Inhibition of platelet binding |
| 09/25/2002 | EP0746312B1 Guanylhydrazones for treating inflammatory conditions |
| 09/25/2002 | EP0702551B1 Compositions and methods for reparation and prevention of fibrotic lesions |
| 09/25/2002 | CN1371391A Heparin compositions that inhibit clot associated coagulation factors |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371388A Hexapeptide with stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation differentiation and apoptosis |
| 09/25/2002 | CN1371375A Tricycle dcompounds having spiro union |
| 09/25/2002 | CN1371359A Aminobenzophenones as inhibitors IL-1 beta and TNF-alpha |
| 09/25/2002 | CN1371285A Methods and compounds for treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 09/25/2002 | CN1371277A Pharmaceutical tramadol salts |
| 09/25/2002 | CN1370598A Application of calcitonin relative gene polypeptide in treating beart failure and cardiovascular disease |
| 09/25/2002 | CN1370590A Fleshy-root gentian tea |
| 09/25/2002 | CN1370583A Blood pressure-reducing rhodiola root medicinal tea |
| 09/25/2002 | CN1370573A Xinning capsule |
| 09/25/2002 | CN1370546A Antilipemic agent and its prepn |
| 09/25/2002 | CN1370532A Maleic amlodipine besylate tablet as cardiovascular disease treating medicine and its prepn |
| 09/25/2002 | CN1370531A Combined therapy |
| 09/25/2002 | CN1370526A Treating method of nuclear factor-KB mediated diseases and dysfuction |